scholarly journals C-reactive protein gene 1846C>T polymorphism is associated with increased risk and clinical features of lung cancer: a case–control study

2019 ◽  
Vol 39 (6) ◽  
Author(s):  
Chen Chen ◽  
Jing-Ni Liu ◽  
Jian-Qiang Zhao ◽  
Bao Zang
Keyword(s):  
Lung Cancer ◽  
Case Control Study ◽  
Case Control ◽  
Lung Carcinogenesis ◽  
C Reactive Protein ◽  
Chinese Han ◽  
Reactive Protein ◽  
Potential Marker ◽  
Increased Risk ◽  
Control Study

AbstractChronic inflammation plays an important role in lung carcinogenesis. Recently, several studies investigated the association of C-reactive protein (CRP) gene 1846C>T polymorphism and lung cancer (LC) risk, but with conflicting findings. In the present study, we conducted this case–control study with 408 LC patients and 472 healthy controls in a Chinese Han population. Genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLR) method. Our data found that CRP gene 1846C>T polymorphism increased the risk of LC. Subgroup analyses obtained significant associations among the groups of males, ≥50 years old, smoking, and non-drinkers. Bioinformatics analysis showed that the expression levels of CRP in LC tissues were significantly increased compared with normal tissues. Additionally, the present study found CRP mRNA high expression was associated with worse survival in LC patients. Furthermore, our data indicated that TT genotype of 1846C>T polymorphism was associated with a larger size of tumor and was related with lymphatic metastasis in LC patients. In conclusion, the present study suggests that CRP gene 1846C>T polymorphism is associated with increased risk of LC. CRP gene 1846C>T polymorphism may be a potential marker for the diagnosis of LC.

Serum C-reactive protein and risk of lung cancer: a case–control study

2012 ◽  
Vol 30 (1) ◽  
Author(s):  
Ming Xu ◽  
Minglin Zhu ◽  
Yinggan Du ◽  
Bibo Yan ◽  
Qian Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Control Study ◽  
Case Control ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Control Study

scholarly journals Circulating high sensitivity C reactive protein concentrations and risk of lung cancer: nested case-control study within Lung Cancer Cohort Consortium

BMJ ◽  
2019 ◽  
pp. k4981 ◽  
Author(s):  
David C Muller ◽  
Tricia L Larose ◽  
Allison Hodge ◽  
Florence Guida ◽  
Arnulf Langhammer ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Case Control Study ◽  
Smoking Status ◽  
High Sensitivity ◽  
Case Control ◽  
C Reactive Protein ◽  
Reactive Protein ◽  
Nested Case Control ◽  
Control Study

Abstract Objectives To conduct a comprehensive analysis of prospectively measured circulating high sensitivity C reactive protein (hsCRP) concentration and risk of lung cancer overall, by smoking status (never, former, and current smokers), and histological sub-type. Design Nested case-control study. Setting 20 population based cohort studies in Asia, Europe, Australia, and the United States. Participants 5299 patients with incident lung cancer, with individually incidence density matched controls. Exposure Circulating hsCRP concentrations in prediagnostic serum or plasma samples. Main outcome measure Incident lung cancer diagnosis. Results A positive association between circulating hsCRP concentration and the risk of lung cancer for current (odds ratio associated with a doubling in hsCRP concentration 1.09, 95% confidence interval 1.05 to 1.13) and former smokers (1.09, 1.04 to 1.14) was observed, but not for never smokers (P<0.01 for interaction). This association was strong and consistent across all histological subtypes, except for adenocarcinoma, which was not strongly associated with hsCRP concentration regardless of smoking status (odds ratio for adenocarcinoma overall 0.97, 95% confidence interval 0.94 to 1.01). The association between circulating hsCRP concentration and the risk of lung cancer was strongest in the first two years of follow-up for former and current smokers. Including hsCRP concentration in a risk model, in addition to smoking based variables, did not improve risk discrimination overall, but slightly improved discrimination for cancers diagnosed in the first two years of follow-up. Conclusions Former and current smokers with higher circulating hsCRP concentrations had a higher risk of lung cancer overall. Circulating hsCRP concentration was not associated with the risk of lung adenocarcinoma. Circulating hsCRP concentration could be a prediagnostic marker of lung cancer rather than a causal risk factor.

scholarly journals Interstitial Lung Disease Associated with Lung Cancer: A Case–Control Study

2020 ◽  
Vol 9 (3) ◽  
pp. 700
Author(s):  
Quentin Gibiot ◽  
Isabelle Monnet ◽  
Pierre Levy ◽  
Anne-Laure Brun ◽  
Martine Antoine ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Interstitial Lung Disease ◽  
Lung Disease ◽  
Case Control Study ◽  
Standard Of Care ◽  
Case Control ◽  
Risk Of Death ◽  
Increased Risk ◽  
Two Factors ◽  
Control Study

Interstitial lung disease (ILD) seems to be associated with an increased risk of lung cancer (LC) and to have a poorer prognosis than LC without ILD. The frequency of ILD in an LC cohort and its prognosis implication need to be better elucidated. This retrospective, observational, cohort study evaluated the frequency of ILD among LC patients (LC–ILD) diagnosed over a 2-year period. LC–ILD patients’ characteristics were compared to those with LC without ILD (LC–noILD). Lastly, we conducted a case–control study within this cohort, matching three LC–noILDs to each LC–ILD patient, to evaluate the ILD impact on LC patients’ prognoses. Among 906 LC patients, 49 (5.4%) also had ILD. Comparing LC–ILD to LC–noILD patients, respectively, more were men (85.7% vs. 66.2%; p = 0.02); adenocarcinomas were less frequent (47.1% vs. 58.7%, p = 0.08); median [range] and overall survival was shorter: (9 [range: 0.1–39.4] vs. 17.5 [range: 0.8–50.4] months; p = 0.01). Multivariate analysis (hazard ratio [95% confidence interval]) retained two factors independently associated with LC risk of death: ILD (1.79 [1.22–2.62]; p = 0.003) and standard-of-care management (0.49 [0.33–0.72]; p < 0.001). Approximately 5% of patients with a new LC diagnosis had associated ILD. ILD was a major prognosis factor for LC and should be taken into consideration for LC management. Further studies are needed to determine the best therapeutic strategy for the LC–ILD population.

scholarly journals Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study

2020 ◽  
Vol 23 ◽  
pp. 100375 ◽  
Author(s):  
Qilin Li ◽  
Xiuli Ding ◽  
Geqing Xia ◽  
Heng-Gui Chen ◽  
Fenghua Chen ◽  
...  
Keyword(s):  
Case Control Study ◽  
Case Control ◽  
C Reactive Protein ◽  
Retrospective Case ◽  
Reactive Protein ◽  
Control Study
Sign in / Sign up

Export Citation Format

Share Document